Barclays Maintains Equal-Weight on West Pharmaceutical Servs, Raises Price Target to $275
Benzinga Newsdesk 7 months ago
NewsPrice TargetAnalyst Ratings
Barclays analyst Luke Sergott maintains West Pharmaceutical Servs (NYSE:WST) with a Equal-Weight and raises the price target from $265 to $275.
Barclays analyst Luke Sergott maintains West Pharmaceutical Servs (NYSE:WST) with a Equal-Weight and raises the price target from $265 to $275.